AU699034B2 - New inhibitors of platelet aggregation - Google Patents

New inhibitors of platelet aggregation Download PDF

Info

Publication number
AU699034B2
AU699034B2 AU63751/96A AU6375196A AU699034B2 AU 699034 B2 AU699034 B2 AU 699034B2 AU 63751/96 A AU63751/96 A AU 63751/96A AU 6375196 A AU6375196 A AU 6375196A AU 699034 B2 AU699034 B2 AU 699034B2
Authority
AU
Australia
Prior art keywords
formula
compound
acid
triazolo
propylthio
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU63751/96A
Other languages
English (en)
Other versions
AU6375196A (en
Inventor
David Cox
Anthony Ingall
Paul Willis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
Astra Pharmaceuticals Ltd
Astra Pharmaceutical Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9514074.5A external-priority patent/GB9514074D0/en
Priority claimed from GBGB9520311.3A external-priority patent/GB9520311D0/en
Priority claimed from GBGB9522837.5A external-priority patent/GB9522837D0/en
Application filed by Astra Pharmaceuticals Ltd, Astra Pharmaceutical Products Inc filed Critical Astra Pharmaceuticals Ltd
Publication of AU6375196A publication Critical patent/AU6375196A/en
Application granted granted Critical
Publication of AU699034B2 publication Critical patent/AU699034B2/en
Assigned to ASTRAZENECA AB reassignment ASTRAZENECA AB Alteration of Name(s) in Register under S187 Assignors: ASTRA PHARMACEUTICALS LIMITED
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU63751/96A 1995-07-11 1996-07-04 New inhibitors of platelet aggregation Ceased AU699034B2 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GBGB9514074.5A GB9514074D0 (en) 1995-07-11 1995-07-11 Compounds
GB9514074 1995-07-11
GBGB9520311.3A GB9520311D0 (en) 1995-10-05 1995-10-05 Compounds
GB9520311 1995-10-05
GBGB9522837.5A GB9522837D0 (en) 1995-11-08 1995-11-08 Compounds
GB9522837 1995-11-08
PCT/SE1996/000911 WO1997003084A1 (en) 1995-07-11 1996-07-04 New inhibitors of platelet aggregation

Publications (2)

Publication Number Publication Date
AU6375196A AU6375196A (en) 1997-02-10
AU699034B2 true AU699034B2 (en) 1998-11-19

Family

ID=27267806

Family Applications (1)

Application Number Title Priority Date Filing Date
AU63751/96A Ceased AU699034B2 (en) 1995-07-11 1996-07-04 New inhibitors of platelet aggregation

Country Status (25)

Country Link
US (1) US5747496A (https=)
EP (1) EP0840740B1 (https=)
JP (1) JP4084415B2 (https=)
KR (1) KR100444123B1 (https=)
CN (1) CN1069321C (https=)
AR (1) AR003453A1 (https=)
AT (1) ATE217010T1 (https=)
AU (1) AU699034B2 (https=)
BR (1) BR9609467A (https=)
CA (1) CA2226758A1 (https=)
CZ (1) CZ297200B6 (https=)
DE (1) DE69621021T2 (https=)
EE (1) EE03616B1 (https=)
HU (1) HU221880B1 (https=)
IL (1) IL122814A (https=)
IS (1) IS1790B (https=)
MY (1) MY116542A (https=)
NO (1) NO310624B1 (https=)
NZ (1) NZ312258A (https=)
PL (1) PL182680B1 (https=)
SA (1) SA96170272B1 (https=)
SK (1) SK283206B6 (https=)
TR (1) TR199800019T1 (https=)
TW (1) TW427996B (https=)
WO (1) WO1997003084A1 (https=)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0946561B1 (en) * 1996-12-20 2002-02-13 AstraZeneca AB Triazolo(4,5-d)pyrimidinyl derivatives and their use as medicaments
SE9702772D0 (sv) * 1997-07-22 1997-07-22 Astra Pharma Prod Novel compounds
SE9702773D0 (sv) 1997-07-22 1997-07-22 Astra Pharma Prod Novel compounds
SE9702774D0 (sv) * 1997-07-22 1997-07-22 Astra Pharma Prod Novel compounds
AR017014A1 (es) * 1997-07-22 2001-08-22 Astrazeneca Ab Compuestos de triazolo [4,5-d]pirimidina, composiciones farmaceuticas, uso de los mismos para preparar medicamentos y procesos para la preparacionde dichos compuestos
NZ505250A (en) * 1998-02-17 2002-10-25 Astrazeneca Uk Ltd Novel triazolo(4,5-d) pyrimidine compounds and pharmaceuticals thereof.
SE9802574D0 (sv) * 1998-07-17 1998-07-17 Astra Pharma Prod Novel compounds
TWI229674B (en) * 1998-12-04 2005-03-21 Astra Pharma Prod Novel triazolo[4,5-d]pyrimidine compounds, pharmaceutical composition containing the same, their process for preparation and uses
SE9904128D0 (sv) * 1999-11-15 1999-11-15 Astra Pharma Prod Novel compounds
SE9904129D0 (sv) 1999-11-15 1999-11-15 Astra Pharma Prod Novel compounds
SE9904377D0 (sv) * 1999-12-01 1999-12-01 Astra Pharma Prod Pharmaceutical combinations
GB0013488D0 (en) * 2000-06-02 2000-07-26 Astrazeneca Ab Chemical compound
GB0013407D0 (en) * 2000-06-02 2000-07-26 Astrazeneca Ab Forms of a chemical compound
US7132408B2 (en) 2000-08-21 2006-11-07 Inspire Pharmaceuticals, Inc. Composition and method for inhibiting platelet aggregation
AR039558A1 (es) * 2000-08-21 2005-02-23 Inspire Pharmaceuticals Inc Composiciones y metodo para el tratamiento de glaucoma o hipertension ocular
US7018985B1 (en) 2000-08-21 2006-03-28 Inspire Pharmaceuticals, Inc. Composition and method for inhibiting platelet aggregation
US7115585B2 (en) * 2000-08-21 2006-10-03 Inspire Pharmaceuticals, Inc. Compositions for treating epithelial and retinal tissue diseases
US7452870B2 (en) * 2000-08-21 2008-11-18 Inspire Pharmaceuticals, Inc. Drug-eluting stents coated with P2Y12 receptor antagonist compound
US6897201B2 (en) 2000-08-21 2005-05-24 Inspire Pharmaceuticals, Inc. Compositions and methods for the treatment of glaucoma or ocular hypertension
GB0100624D0 (en) * 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical compounds VII
SE0101932D0 (sv) * 2001-05-31 2001-05-31 Astrazeneca Ab Pharmaceutical combinations
US20020169730A1 (en) * 2001-08-29 2002-11-14 Emmanuel Lazaridis Methods for classifying objects and identifying latent classes
US7435724B2 (en) 2002-02-27 2008-10-14 Inspire Pharmaceutical, Inc. Degradation-resistant mononucleoside phosphate compounds
EP1618108A2 (en) * 2003-04-09 2006-01-25 Biogen Idec MA Inc. Triazolo[1,5-a]pyrimidines and pyrazolo[1,5-a]pyrimidines useful as a2a adenosine receptor antagonists
US7674791B2 (en) * 2003-04-09 2010-03-09 Biogen Idec Ma Inc. Triazolopyrazines and methods of making and using the same
EP1615930A2 (en) * 2003-04-09 2006-01-18 Biogen Idec MA, Inc. Triazolotriazines and pyrazolotriazines useful as a2a adenosine receptor antagonists
US20070010522A1 (en) * 2003-04-09 2007-01-11 Chi Vu Triazolo[1,5-c]pyrimidines and pyrazolo[1,5-c]pyrimidines useful as a2a adenosine receptor antagonists
WO2004092173A2 (en) * 2003-04-09 2004-10-28 Biogen Idec Ma Inc. A2a adenosine receptor antagonists
US7504497B2 (en) * 2003-10-21 2009-03-17 Inspire Pharmaceuticals, Inc. Orally bioavailable compounds and methods for inhibiting platelet aggregation
US7749981B2 (en) * 2003-10-21 2010-07-06 Inspire Pharmaceuticals, Inc. Drug-eluting stents coated with non-nucleotide P2Y12 receptor antagonist compound
AU2004284098B2 (en) * 2003-10-21 2009-07-16 Inspire Pharmaceuticals, Inc. Tetrahydro-furo [3,4-d] dioxole compounds and compositions and method for inhibiting platelet aggregation
US7335648B2 (en) * 2003-10-21 2008-02-26 Inspire Pharmaceuticals, Inc. Non-nucleotide composition and method for inhibiting platelet aggregation
GB2422782A (en) * 2003-10-21 2006-08-09 Inspire Pharmaceuticals Inc Non-nucleotide compositions and method for treating pain
US7932376B2 (en) * 2005-05-05 2011-04-26 Inspire Pharmaceuticals, Inc. Pyrimidine-based non-nucleotide composition and method for inhibiting platelet aggregation
JP2010508350A (ja) * 2006-10-31 2010-03-18 ヤンセン ファーマシューティカ エヌ．ベー． Ａｄｐｐ２ｙ１２レセプターアンタゴニストとしてのトリアゾロピリミジン誘導体
UA100864C2 (uk) * 2007-12-03 2013-02-11 Астразенека Аб Спосіб лікування або запобігання аневризмі черевної аорти
GB0906579D0 (en) * 2009-04-16 2009-05-20 Vernalis R&D Ltd Pharmaceuticals, compositions and methods of making and using the same
US8470834B2 (en) * 2008-08-20 2013-06-25 Merck Sharp & Dohme Corp. AZO-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
CA2788072A1 (en) 2010-02-16 2011-08-25 Actavis Group Ptc Ehf Improved processes for preparing ticagrelor intermediate, 4,6-dichloro-5-nitro-2-(propylthio)pyrimidine
MX2014006190A (es) 2011-11-30 2014-07-10 Actavis Group Ptc Ehf Nueva forma cristalina de ticagrelor y proceso para la preparacion de la misma.
WO2014083139A1 (en) 2012-11-29 2014-06-05 Actavis Group Ptc Ehf Novel amorphous form of ticagrelor
WO2014206187A1 (zh) 2013-06-24 2014-12-31 苏州明锐医药科技有限公司 替卡格雷及其中间体的制备方法
JP6145574B2 (ja) * 2013-06-27 2017-06-14 スーヂョウ ミラクファーマ テクノロジ カンパニー リミテッドＳｕｚｈｏｕ Ｍｉｒａｃｐｈａｒｍａ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏ．，Ｌｔｄ． チカグレロールの調製方法
CN105061431B (zh) * 2015-07-28 2017-03-29 山东百诺医药股份有限公司 6‑n‑（2‑（甲硫基）乙基）‑2‑（（3,3,3‑三氟丙基）硫代）‑9h‑嘌呤及其制备方法和应用
CN112915063B (zh) * 2021-01-25 2022-12-20 刘红枚 一种用于治疗子宫平滑肌高频率强直性收缩相关疾病的化合物
CN112876485A (zh) * 2021-01-25 2021-06-01 郭丽伟 一种用于治疗子宫平滑肌高频率强直性收缩相关疾病的化合物
RU2770405C1 (ru) * 2021-07-05 2022-04-15 федеральное государственное бюджетное образовательное учреждение высшего образования "Башкирский государственный медицинский университет" Министерства здравоохранения Российской Федерации Производные триазола, проявляющие антиагрегационную активность

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4742064A (en) * 1985-09-10 1988-05-03 Regents Of The University Of Minnesota Antiviral carbocyclic analogs of xylofuranosylpurines
GB8826205D0 (en) * 1988-11-09 1988-12-14 Wellcome Found Heterocyclic compounds
JP2619710B2 (ja) * 1989-02-27 1997-06-11 日本製紙 株式会社 ２′，３′−ジデオキシプリンヌクレオシド類の製造方法
EP0684953A4 (en) * 1993-02-03 1999-12-22 Gensia Inc ADENOSINE KINASE INHIBITORS COMPRISING LYXOFURANOSYL DERIVATIVES.
IL108523A0 (en) * 1993-02-03 1994-05-30 Gensia Inc Pharmaceutical compositions containing adenosine kinase inhibitors for preventing or treating conditions involving inflammatory responses and pain

Also Published As

Publication number Publication date
CA2226758A1 (en) 1997-01-30
IS4647A (is) 1998-01-08
WO1997003084A1 (en) 1997-01-30
BR9609467A (pt) 1999-03-02
JP4084415B2 (ja) 2008-04-30
DE69621021D1 (de) 2002-06-06
DE69621021T2 (de) 2002-10-31
AU6375196A (en) 1997-02-10
US5747496A (en) 1998-05-05
PL182680B1 (pl) 2002-02-28
KR19990028885A (ko) 1999-04-15
HUP9802448A2 (hu) 1999-05-28
SK283206B6 (sk) 2003-03-04
NZ312258A (en) 1999-08-30
JPH11508914A (ja) 1999-08-03
EP0840740B1 (en) 2002-05-02
CN1069321C (zh) 2001-08-08
MX9800308A (es) 1998-09-30
IS1790B (is) 2001-11-28
IL122814A0 (en) 1998-08-16
CZ2598A3 (cs) 1998-08-12
SA96170272B1 (ar) 2006-06-04
AR003453A1 (es) 1998-08-05
HUP9802448A3 (en) 2000-03-28
NO980080L (no) 1998-03-06
TW427996B (en) 2001-04-01
SK2398A3 (en) 1999-01-11
MY116542A (en) 2004-02-28
TR199800019T1 (xx) 1998-05-21
KR100444123B1 (ko) 2004-10-14
EE9800026A (et) 1998-08-17
HU221880B1 (hu) 2003-02-28
ATE217010T1 (de) 2002-05-15
EE03616B1 (et) 2002-02-15
EP0840740A1 (en) 1998-05-13
PL324396A1 (en) 1998-05-25
CN1195353A (zh) 1998-10-07
IL122814A (en) 2001-04-30
NO310624B1 (no) 2001-07-30
CZ297200B6 (cs) 2006-09-13
NO980080D0 (no) 1998-01-08

Similar Documents

Publication Publication Date Title
AU699034B2 (en) New inhibitors of platelet aggregation
KR100315612B1 (ko) N-알킬-2-치환아데노신트리포스페이트동족체
US4579849A (en) N-alkylguanine acyclonucleosides as antiviral agents
US6069132A (en) Phosphazole compounds
HUP0100202A2 (hu) Új triazolo[4,5-d]pirimidin-származékok, eljárás előállításukra, alkalmazásuk és az ezeket tartalmazó gyógyszerkészítmények
EP0579643A1 (en) Atp analogues
AU8370798A (en) Novel compounds
JPH01501864A (ja) 抗ウイルス剤
JPH0320291A (ja) 新規化合物、その製法及びそれを含む医薬組成物
RU2174518C2 (ru) Производные 3-н-1,2,3-триазоло-[4,5-d]пиримидина, фармацевтическая композиция и способ их получения
Groziak et al. Definitive Solution Structures for the 6-Formylated Versions of 1-(βD-Ribofuranosyl)-, 1-(2′-Deoxy-β-D-Ribofuranosyl)-, and 1-β-D-Arabinofuranosyluracil, and of Thymidine
JPH02247191A (ja) 抗レトロウイルス剤としてのプリンおよびピリミジン非環状ヌクレオシドの環状モノホスフエート類
MXPA98000308A (en) New plaque aggregation inhibitors
UA64697C2 (en) Platelet aggregation inhibitors
AU648885C (en) ATP analogues
Wang Synthesis and biochemical studies of ring-expanded (''Fat'') nucleoside analogues containing the imidazo-(4, 5-e)(1, 3) diazepine ring system
HK1002936B (en) N-alkyl-2-substituted atp analogues

Legal Events

Date Code Title Description
PC Assignment registered

Owner name: ASTRAZENECA AB

Free format text: FORMER OWNER WAS: ASTRA PHARMACEUTICALS LTD.